ResearcherCedars-Sinai Medical CenterNo recent work listed
Deepti Dhall
Matched on OpenAlex author ID A5069065644. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper
Papers 5
- Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
- Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cro… Co-author DOI 10.1097/pas.0000000000001723↗
- Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Co-author DOI 10.1245/s10434-017-6076-z↗
- Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. Co-author DOI 10.3978/j.issn.2078-6891.2015.109↗
- Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. First author DOI 10.1038/srep16759↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Olca Baştürk · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Kee‐Taek Jang · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Daniela S. Allende · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Volkan N. Adsay · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Grace Kim · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Jiaqi Shi · 2 shared papers, 2021–2022 · strength 0.27
- Paper Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal A… DOI 10.1097/pas.0000000000001723↗
- Paper Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations F… DOI 10.1097/pas.0000000000001853↗
- Andrew Eugene Hendifar · 2 shared papers, 2016–2017 · strength 0.12
- Paper Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant The… DOI 10.1245/s10434-017-6076-z↗
- Paper Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications fo… DOI 10.3978/j.issn.2078-6891.2015.109↗
- Joanne K.L. Rutgers · 2 shared papers, 2016–2017 · strength 0.12
- Paper Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant The… DOI 10.1245/s10434-017-6076-z↗
- Paper Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications fo… DOI 10.3978/j.issn.2078-6891.2015.109↗
- Nicholas N. Nissen · 2 shared papers, 2016–2017 · strength 0.12
- Paper Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant The… DOI 10.1245/s10434-017-6076-z↗
- Paper Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications fo… DOI 10.3978/j.issn.2078-6891.2015.109↗
- Richard Tuli · 2 shared papers, 2016–2017 · strength 0.12
- Paper Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant The… DOI 10.1245/s10434-017-6076-z↗
- Paper Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications fo… DOI 10.3978/j.issn.2078-6891.2015.109↗
- Arsen Osipov · 2 shared papers, 2016–2017 · strength 0.12
- Paper Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant The… DOI 10.1245/s10434-017-6076-z↗
- Paper Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications fo… DOI 10.3978/j.issn.2078-6891.2015.109↗
- Huamin Wang · 1 shared paper, 2022 · strength 0.12
- Runjan Chetty · 1 shared paper, 2022 · strength 0.12
- Yoko Matsuda · 1 shared paper, 2022 · strength 0.12
- Michelle Dian Reid · 1 shared paper, 2022 · strength 0.12
- Rondell Patrell Graham · 1 shared paper, 2022 · strength 0.12
- Alyssa M. Krasinskas · 1 shared paper, 2022 · strength 0.12
- Vikram Deshpande · 1 shared paper, 2022 · strength 0.12
- Claudio Luchini · 1 shared paper, 2022 · strength 0.12
- Iréne Esposito · 1 shared paper, 2022 · strength 0.12
- Ralph H. Hruban · 1 shared paper, 2022 · strength 0.12
- Susan Morvaridi · 1 shared paper, 2015 · strength 0.06
- Qiang Wang · 1 shared paper, 2015 · strength 0.06
- Stephen Jacob Pandol · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.